Insider trade

Cytokinetics (CYTK): Officer sold ~$145K

Andrew Callos, Officer at Cytokinetics, sold ~$145K of Cytokinetics shares.

~$145K
Approx. value · 3,341 sh @ $43.27
64K
Holds after · shares reported
Traded
Mar 6, 2025
Filed
Mar 8, 2025

What stands out in this filing

  • The sale was 4.9% of the shares this insider held before it; the filing reports 64,434 shares afterwards.
  • 3,341 shares at an average of $43.27 each, as reported on the form.
  • Footnote references vesting of compensation awards.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jan 7, 2025InsiderOfficer sold ~$99K of CYTK shares in the open market
  2. Jan 21, 2025InsiderOfficer sold ~$92K of CYTK shares in the open market
  3. Feb 4, 2025InsiderOfficer sold ~$96K of CYTK shares in the open market
  4. Feb 18, 2025InsiderOfficer sold ~$92K of CYTK shares in the open market
  5. Mar 3, 2025Insider · 3 peopleInsiders: 3 sales (~$528K)
  6. Mar 4, 2025Insider · 2 peopleInsiders: 2 sales (~$123K)
  7. Mar 5, 2025InsiderCEO sold ~$1.08M of CYTK shares in the open market
  8. Mar 6, 2025 · this disclosureInsiderOfficer sold ~$145K of CYTK shares in the open market

What came next

  1. Mar 6, 2025Insider · 2 peopleInsiders: 2 sales (~$1.1M)
  2. Mar 13, 2025InsiderOfficer sold ~$1.17M of CYTK shares in the open market
  3. Mar 14, 2025InsiderOfficer sold ~$4.5K of CYTK shares in the open market
  4. Mar 17, 2025Insider · 3 peopleInsiders: 5 sales (~$2.9M)
  5. Mar 18, 2025InsiderOfficer sold ~$87K of CYTK shares in the open market
  6. Mar 31, 2025InsiderCEO sold ~$611K of CYTK shares in the open market
  7. Apr 3, 2025InsiderDirector sold ~$18K of CYTK shares in the open market
  8. Apr 7, 2025InsiderOfficer sold ~$103K of CYTK shares in the open market
  9. Apr 8, 2025InsiderOfficer sold ~$72K of CYTK shares in the open market
  10. Apr 10, 2025InsiderCEO sold ~$184K of CYTK shares in the open market
  11. Apr 15, 2025InsiderDirector sold ~$123K of CYTK shares in the open market
  12. Apr 21, 2025InsiderDirector sold ~$769K of CYTK shares in the open market
  13. Apr 22, 2025InsiderOfficer sold ~$76K of CYTK shares in the open market
  14. Apr 29, 2025InsiderCEO sold ~$205K of CYTK shares in the open market
  15. May 5, 2025InsiderOfficer sold ~$147K of CYTK shares in the open market
  16. May 6, 2025InsiderOfficer sold ~$70K of CYTK shares in the open market
  17. May 15, 2025InsiderDirector sold ~$43K of CYTK shares in the open market
  18. May 16, 2025InsiderCEO sold ~$155K of CYTK shares in the open market
  19. May 20, 2025InsiderOfficer sold ~$64K of CYTK shares in the open market
  20. Jun 2, 2025InsiderCEO sold ~$156K of CYTK shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Cytokinetics

For Cytokinetics, OQRO holds 26 insider filings (SEC Form 4 or Form 144) and 1 Congress trade report dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CYTK page.

Other recent filings by Andrew Callos, EVP, Chief Commercial Officer

The full history of Andrew Callos, EVP, Chief Commercial Officer is on the profile page.

How this filing works

Explore the data

Common questions

Which Cytokinetics (CYTK) insider traded, and how much?

Andrew Callos, Officer at Cytokinetics, sold ~$145K of Cytokinetics shares. 3,341 shares at $43.27.

When did it happen, and when was it made public?

Traded: Mar 6, 2025. Filed: Mar 8, 2025. That is 2 days between the two dates.

What stands out in this filing?

The sale was 4.9% of the shares this insider held before it; the filing reports 64,434 shares afterwards. 3,341 shares at an average of $43.27 each, as reported on the form. Footnote references vesting of compensation awards.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Cytokinetics recently?

For Cytokinetics, OQRO holds 26 insider filings (SEC Form 4 or Form 144) and 1 Congress trade report dated in the last 90 days. They are listed on the CYTK page.

Does this mean CYTK stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Cytokinetics

Everything OQRO holds on this company is on its CYTK page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data